Elevated plasma aldosterone (Aldo) levels are associated with greater risk of cardiac ischemic events and cardiovascular mortality. Adenosine-mediated coronary vasodilation is a critical cardioprotective mechanism during ischemia; however, whether this response is impaired by increased Aldo is unclear. We hypothesized that chronic Aldo impairs coronary adenosine-mediated vasodilation via downregulation of vascular K(+) channels. Male C57BL/6J mice were treated with vehicle (Con) or subpressor Aldo for 4 wk. Coronary artery function, assessed by wire myography, revealed Aldo-induced reductions in vasodilation to adenosine and the endothelium-dependent vasodilator acetylcholine but not to the nitric oxide donor sodium nitroprusside. Coronary vasoconstriction to endothelin-1 and the thromboxane A(2) mimetic U-46619 was unchanged by Aldo. Additional mechanistic studies revealed impaired adenosine A(2A), not A(2B), receptor-dependent vasodilation by Aldo with a tendency for Aldo-induced reduction of coronary A(2A) gene expression. Adenylate cyclase inhibition attenuated coronary adenosine dilation but did not eliminate group differences, and adenosine-stimulated vascular cAMP production was similar between Con and Aldo mice. Similarly, blockade of inward rectifier K(+) channels reduced but did not eliminate group differences in adenosine dilation whereas group differences were eliminated by blockade of Ca(2+)-activated K(+) (K(Ca)) channels that blunted and abrogated adenosine and A(2A)-dependent dilation, respectively. Gene expression of several coronary K(Ca) channels was reduced by Aldo. Together, these data demonstrate Aldo-induced impairment of adenosine-mediated coronary vasodilation involving blunted A(2A)-K(Ca)-dependent vasodilation, independent of blood pressure, providing important insights into the link between plasma Aldo and cardiac mortality and rationale for aldosterone antagonist use to preserve coronary microvascular function. NEW & NOTEWORTHY Increased plasma aldosterone levels are associated with worsened cardiac outcomes in diverse patient groups by unclear mechanisms. We identified that, in male mice, elevated aldosterone impairs coronary adenosine-mediated vasodilation, an important cardioprotective mechanism. This aldosterone-induced impairment involves reduced adenosine A(2A), not A(2B), receptor-dependent vasodilation associated with downregulation of coronary K(Ca) channels and does not involve altered adenylate cyclase/cAMP signaling. Importantly, this effect of aldosterone occurred independent of changes in coronary vasoconstrictor responsiveness and blood pressure. Listen to this article’s corresponding podcast at https://ajpheart.podbean.com/e/attenuation-of-coronary-adenosine-dilation-by-aldosterone/.
